Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 11, 2023

BUY
$33.3 - $44.82 $246,419 - $331,668
7,400 New
7,400 $275,000
Q2 2022

Aug 12, 2022

BUY
$38.49 - $76.21 $895,508 - $1.77 Million
23,266 Added 31.94%
96,118 $4.98 Million
Q1 2022

May 13, 2022

SELL
$58.27 - $118.99 $576,173 - $1.18 Million
-9,888 Reduced 11.95%
72,852 $5.29 Million
Q4 2021

Feb 11, 2022

BUY
$100.76 - $138.36 $528,486 - $725,698
5,245 Added 6.77%
82,740 $9.8 Million
Q3 2021

Nov 10, 2021

BUY
$132.37 - $176.78 $3.62 Million - $4.84 Million
27,354 Added 54.55%
77,495 $10.4 Million
Q2 2021

Aug 16, 2021

BUY
$60.88 - $161.91 $728,855 - $1.94 Million
11,972 Added 31.37%
50,141 $8.12 Million
Q1 2021

May 13, 2021

SELL
$46.59 - $83.68 $163,996 - $294,553
-3,520 Reduced 8.44%
38,169 $3.06 Million
Q4 2020

Feb 16, 2021

BUY
$18.83 - $63.53 $785,003 - $2.65 Million
41,689 New
41,689 $2.27 Million
Q2 2020

Aug 14, 2020

SELL
$11.14 - $22.87 $764,148 - $1.57 Million
-68,595 Closed
0 $0
Q1 2020

May 14, 2020

SELL
$9.44 - $15.58 $326,510 - $538,881
-34,588 Reduced 33.52%
68,595 $839,000
Q4 2019

Feb 13, 2020

BUY
$10.43 - $17.67 $123,011 - $208,399
11,794 Added 12.91%
103,183 $1.51 Million
Q3 2019

Nov 13, 2019

SELL
$13.07 - $18.51 $1.21 Million - $1.71 Million
-92,314 Reduced 50.25%
91,389 $1.22 Million
Q2 2019

Aug 08, 2019

BUY
$13.88 - $18.41 $177,358 - $235,242
12,778 Added 7.48%
183,703 $3.01 Million
Q1 2019

May 13, 2019

BUY
$12.79 - $17.62 $543,997 - $749,431
42,533 Added 33.13%
170,925 $2.92 Million
Q4 2018

Feb 14, 2019

BUY
$11.39 - $27.13 $76,745 - $182,801
6,738 Added 5.54%
128,392 $1.75 Million
Q3 2018

Nov 13, 2018

BUY
$25.78 - $32.6 $1.08 Million - $1.36 Million
41,765 Added 52.28%
121,654 $3.48 Million
Q2 2018

Aug 13, 2018

BUY
$20.02 - $30.79 $1.6 Million - $2.46 Million
79,889 New
79,889 $2.19 Million

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $926M
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Allianz Asset Management Gmb H Portfolio

Follow Allianz Asset Management Gmb H and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Allianz Asset Management Gmb H, based on Form 13F filings with the SEC.

News

Stay updated on Allianz Asset Management Gmb H with notifications on news.